Tiziana Life Sciences’ intranasal foralumab modulates T-cell function to reduce lung inflammation. Credit: NIAID/NIH / commons.wikimedia.org.

Biotechnology company Tiziana Life Sciences has revealed plans to assess intranasal foralumab as a potential treatment for long Covid.

Long Covid is a health condition characterised by the continuation or development of new symptoms three months after an initial SARS-CoV-2 infection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The work is supported by the role of foralumab in dampening activated microglia cells, said to be an important component of the pathogenesis of this disease.

Foralumab is a fully human anti-CD3 monoclonal antibody, which works by binding to the T-cell receptor and regulating T-cell function to reduce pulmonary inflammation.

This will suppress the effector characteristics in multiple immune cell subsets. The effect was observed in patients with Covid-19 and multiple sclerosis, and also in healthy participants.

Long Covid is causing complications for patients and is estimated to cost the US healthcare system almost $2.6tn.

Tiziana Life Sciences chief medical officer Matthew Davis said: “We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA.

“The use of PET scans will allow us to determine if intranasal foralumab will decrease activated microglia in patients with long Covid after three months of administration.

“After refining our clinical protocols, we need to discuss this approach with the FDA and plan to file an IND in 4Q 2023.”

Phase II trials of intranasal foralumab are anticipated to commence in the third quarter of 2023 in inactive secondary progressive multiple sclerosis (SPMS) patients.

In 2021, Tiziana Life Sciences and FHI Clinical signed an agreement to conduct a Phase II proof-of-concept clinical trial of intranasal foralumab in severe Covid-19 patients hospitalised with pulmonary inflammation in Brazil.